Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers

Miranda van Rijen; Marc Bonten; Richard Wenzel; Jan Kluytmans

doi:10.1002/14651858.CD006216.pub2

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Respuestas clínicas Cochrane
Guías
Temas

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Figure 1

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 Nosocomial S. aureus infections among patients with S. aureus nasal carriage, Outcome 1 Nosocomial S. aureus infection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Nosocomial S. aureus infections among patients with S. aureus nasal carriage, Outcome 2 Nosocomial S. aureus infection (High quality studies).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Nosocomial S. aureus infections among surgical patients with S. aureus nasal carriage, Outcome 1 Nosocomial S. aureus infection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.2

Comparison 2 Nosocomial S. aureus infections among surgical patients with S. aureus nasal carriage, Outcome 2 Nosocomial S. aureus infection (exclude Garcia).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.3

Comparison 2 Nosocomial S. aureus infections among surgical patients with S. aureus nasal carriage, Outcome 3 Nosocomial S. aureus surgical site infection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.1

Comparison 3 Nosocomial S. aureus infections among dialysis patients with S. aureus nasal carriage, Outcome 1 Nosocomial S. aureus infections.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.1

Comparison 4 Nosocomial S. aureus infections among CAPD patients: a comparison of mupirocin to neomycin, Outcome 1 Nosocomial S. aureus infections.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 5.1

Comparison 5 Mortality among patients with S. aureus nasal carriage, Outcome 1 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 6.1

Comparison 6 Infection rate caused by other micro‐organisms than S. aureus: mupirocin compared with control, Outcome 1 Infection rate caused by other micro‐organisms than S. aureus.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 6.2

Comparison 6 Infection rate caused by other micro‐organisms than S. aureus: mupirocin compared with control, Outcome 2 Infection rate caused by other gram‐positive micro‐organisms than S. aureus.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 6.3

Comparison 6 Infection rate caused by other micro‐organisms than S. aureus: mupirocin compared with control, Outcome 3 Infection rate caused by gram‐negative micro‐organisms.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 7.1

Comparison 7 Infection rate caused by other micro‐organisms than S. aureus: a comparison of mupirocin to neomycin, Outcome 1 Infection rate caused by other micro‐organisms than S. aureus.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Nosocomial S. aureus infections among patients with S. aureus nasal carriage

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Nosocomial S. aureus infection Show forest plot	8	3374	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.43, 0.70]

2 Nosocomial S. aureus infection (High quality studies) Show forest plot	4	2909	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.47, 1.00]

Comparison 1. Nosocomial S. aureus infections among patients with S. aureus nasal carriage

Ir a la tabla de la revisión

Comparison 2. Nosocomial S. aureus infections among surgical patients with S. aureus nasal carriage

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Nosocomial S. aureus infection Show forest plot	4	1372	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.34, 0.88]

2 Nosocomial S. aureus infection (exclude Garcia) Show forest plot	3	1307	Risk Ratio (M‐H, Fixed, 95% CI)	0.56 [0.34, 0.91]

3 Nosocomial S. aureus surgical site infection Show forest plot	4	1374	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.38, 1.04]

Comparison 2. Nosocomial S. aureus infections among surgical patients with S. aureus nasal carriage

Ir a la tabla de la revisión

Comparison 3. Nosocomial S. aureus infections among dialysis patients with S. aureus nasal carriage

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Nosocomial S. aureus infections Show forest plot	2	302	Risk Ratio (M‐H, Fixed, 95% CI)	0.44 [0.32, 0.62]

Comparison 3. Nosocomial S. aureus infections among dialysis patients with S. aureus nasal carriage

Ir a la tabla de la revisión

Comparison 4. Nosocomial S. aureus infections among CAPD patients: a comparison of mupirocin to neomycin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Nosocomial S. aureus infections Show forest plot	1	22	Risk Ratio (M‐H, Fixed, 95% CI)	0.42 [0.04, 3.95]

Comparison 4. Nosocomial S. aureus infections among CAPD patients: a comparison of mupirocin to neomycin

Ir a la tabla de la revisión

Comparison 5. Mortality among patients with S. aureus nasal carriage

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality Show forest plot	4	2161	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.64, 1.31]

Comparison 5. Mortality among patients with S. aureus nasal carriage

Ir a la tabla de la revisión

Comparison 6. Infection rate caused by other micro‐organisms than S. aureus: mupirocin compared with control

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Infection rate caused by other micro‐organisms than S. aureus Show forest plot	3	1393	Risk Ratio (M‐H, Fixed, 95% CI)	1.38 [1.11, 1.72]

2 Infection rate caused by other gram‐positive micro‐organisms than S. aureus Show forest plot	2	148	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.55, 1.41]

3 Infection rate caused by gram‐negative micro‐organisms Show forest plot	2	148	Risk Ratio (M‐H, Fixed, 95% CI)	1.65 [0.78, 3.47]

Comparison 6. Infection rate caused by other micro‐organisms than S. aureus: mupirocin compared with control

Ir a la tabla de la revisión

Comparison 7. Infection rate caused by other micro‐organisms than S. aureus: a comparison of mupirocin to neomycin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Infection rate caused by other micro‐organisms than S. aureus Show forest plot	1	22	Risk Ratio (M‐H, Fixed, 95% CI)	1.33 [0.64, 2.79]

Comparison 7. Infection rate caused by other micro‐organisms than S. aureus: a comparison of mupirocin to neomycin

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet